On March 19, 2015, Judge Seeborg of the United States District Court for the Northern District of California denied Amgen Inc.’s motion for a preliminary injunction in the Amgen v. Sandoz case, thereby removing one more hurdle for the market entry of the first biosimilar in the United States. This current dispute hinges on the interpretation of two portions of subsection 42 U.S.C. § 262(l) of the Biologics Price Competition and Innovation Act.

Read more from Paul A. Calvo, Ph.D. and Timothy J. Shea, Jr. in the attached pdf.